

# Washed blood components in adult acute leukemia

<b>Submission date</b> 02/12/2004	<b>Recruitment status</b> No longer recruiting	<input type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol
<b>Registration date</b> 06/12/2004	<b>Overall study status</b> Completed	<input type="checkbox"/> Statistical analysis plan <input checked="" type="checkbox"/> Results
<b>Last Edited</b> 14/08/2009	<b>Condition category</b> Cancer	<input type="checkbox"/> Individual participant data

**Plain English summary of protocol**  
Not provided at time of registration

## Contact information

**Type(s)**  
Scientific

**Contact name**  
Dr Neil Blumberg

**Contact details**  
601 Elmwood Avenue  
Box 608  
Rochester  
United States of America  
14642  
+1 585 275 9656  
neil\_blumberg@urmc.rochester.edu

## Additional identifiers

**EudraCT/CTIS number**

**IRAS number**

**ClinicalTrials.gov number**

**Secondary identifying numbers**  
N/A

# Study information

## Scientific Title

## Study objectives

Not provided at time of registration

## Ethics approval required

Old ethics approval format

## Ethics approval(s)

Not provided at time of registration

## Study design

Randomised active controlled parallel group trial

## Primary study design

Interventional

## Secondary study design

Randomised controlled trial

## Study setting(s)

Hospital

## Study type(s)

Treatment

## Participant information sheet

## Health condition(s) or problem(s) studied

Acute Leukemia

## Interventions

The control intervention was leukocyte reduced red cell and platelet transfusions, the standard practice in most hospitals.

The experimental intervention was leukocyte reduced red cell and platelet transfusions that had also been plasma reduced by washing.

## Intervention Type

Other

## Phase

Not Specified

## Primary outcome measure

Added 14/08/09:

1. Platelet transfusion refractoriness
2. Infectious and bleeding complications
3. Overall survival.

### **Secondary outcome measures**

Not provided at time of registration

### **Overall study start date**

01/01/1991

### **Completion date**

31/12/1994

## **Eligibility**

### **Key inclusion criteria**

Adult patients with acute leukemia undergoing full dose remission induction chemotherapy.

### **Participant type(s)**

Patient

### **Age group**

Adult

### **Sex**

Not Specified

### **Target number of participants**

43

### **Key exclusion criteria**

Does not match inclusion criteria

### **Date of first enrolment**

01/01/1991

### **Date of final enrolment**

31/12/1994

## **Locations**

### **Countries of recruitment**

United States of America

### **Study participating centre**

**601 Elmwood Avenue**  
Rochester  
United States of America  
14642

## **Sponsor information**

### **Organisation**

University of Rochester (USA)

### **Sponsor details**

601 Elmwood Avenue  
Rochester  
United States of America  
14642  
neil\_blumberg@urmc.rochester.edu

### **Sponsor type**

University/education

### **ROR**

<https://ror.org/022kthw22>

## **Funder(s)**

### **Funder type**

University/education

### **Funder Name**

University of Rochester (USA)

### **Funder Name**

CaridianBCT Inc. (formerly Gambro BCT Inc.) (USA)

## **Results and Publications**

### **Publication and dissemination plan**

Not provided at time of registration

### **Intention to publish date**

## Individual participant data (IPD) sharing plan

### IPD sharing plan summary

Not provided at time of registration

### Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
<a href="#">Results article</a>	results	10/12/2004		Yes	No